JP2021529732A5 - - Google Patents
Info
- Publication number
- JP2021529732A5 JP2021529732A5 JP2020569956A JP2020569956A JP2021529732A5 JP 2021529732 A5 JP2021529732 A5 JP 2021529732A5 JP 2020569956 A JP2020569956 A JP 2020569956A JP 2020569956 A JP2020569956 A JP 2020569956A JP 2021529732 A5 JP2021529732 A5 JP 2021529732A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- pharmaceutical composition
- composition according
- esketamine
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000939A JP2024041855A (ja) | 2018-06-27 | 2024-01-09 | 大うつ病性障害の処置方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690419P | 2018-06-27 | 2018-06-27 | |
| US62/690,419 | 2018-06-27 | ||
| US201862698323P | 2018-07-16 | 2018-07-16 | |
| US62/698,323 | 2018-07-16 | ||
| US201862741564P | 2018-10-05 | 2018-10-05 | |
| US62/741,564 | 2018-10-05 | ||
| US201862769264P | 2018-11-19 | 2018-11-19 | |
| US62/769,264 | 2018-11-19 | ||
| PCT/IB2019/055453 WO2020003195A1 (en) | 2018-06-27 | 2019-06-27 | Method of treating major depressive disorder |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000939A Division JP2024041855A (ja) | 2018-06-27 | 2024-01-09 | 大うつ病性障害の処置方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021529732A JP2021529732A (ja) | 2021-11-04 |
| JP2021529732A5 true JP2021529732A5 (https=) | 2022-04-25 |
Family
ID=67909427
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020569956A Pending JP2021529732A (ja) | 2018-06-27 | 2019-06-27 | 大うつ病性障害の処置方法 |
| JP2024000939A Pending JP2024041855A (ja) | 2018-06-27 | 2024-01-09 | 大うつ病性障害の処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000939A Pending JP2024041855A (ja) | 2018-06-27 | 2024-01-09 | 大うつ病性障害の処置方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12036189B2 (https=) |
| EP (1) | EP3813807A1 (https=) |
| JP (2) | JP2021529732A (https=) |
| KR (1) | KR102793535B1 (https=) |
| CN (1) | CN112188889A (https=) |
| AU (1) | AU2019293515B2 (https=) |
| BR (1) | BR112020023882A2 (https=) |
| CA (1) | CA3103440A1 (https=) |
| IL (1) | IL278759B2 (https=) |
| MX (1) | MX2020012475A (https=) |
| WO (1) | WO2020003195A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE056378T2 (hu) | 2013-09-13 | 2022-02-28 | Univ Chiba Nat Univ Corp | R-Ketamin és sójának alkalmazása gyógyszerekként |
| ES2907692T3 (es) | 2017-12-29 | 2022-04-26 | Celon Pharma Sa | Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento |
| US11980595B2 (en) | 2018-02-15 | 2024-05-14 | National University Corporation Chiba University | Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases |
| WO2019213551A1 (en) | 2018-05-04 | 2019-11-07 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| CN112702995A (zh) | 2018-10-05 | 2021-04-23 | 克雷西奥生物科技有限公司 | 治疗重度抑郁症的艾氯胺酮的治疗方案 |
| EP3863617A1 (en) | 2018-10-11 | 2021-08-18 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
| JP2023507926A (ja) | 2019-12-30 | 2023-02-28 | クレキシオ バイオサイエンシーズ エルティーディー． | 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 |
| EP4084786A1 (en) | 2019-12-30 | 2022-11-09 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH535201A (de) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
| US7399488B2 (en) | 2002-07-05 | 2008-07-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
| AU2007229866A1 (en) | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
| US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| DE102007009888A1 (de) | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
| AU2008286914B2 (en) | 2007-08-13 | 2014-10-02 | Ohemo Life Sciences Inc. | Abuse resistant drugs, method of use and method of making |
| JP2011520815A (ja) | 2008-05-09 | 2011-07-21 | エモリー・ユニバーシテイ | 精神神経障害治療のためのｎｍｄａ受容体拮抗薬 |
| US20110038807A1 (en) | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| WO2013138322A1 (en) | 2012-03-12 | 2013-09-19 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| BR112015000150A2 (pt) | 2012-07-06 | 2017-06-27 | Egalet Ltd | composições farmacêuticas dissuasoras de abuso de liberação controlada |
| US20140079740A1 (en) | 2012-08-02 | 2014-03-20 | ClinPharm Support GmbH | Oral transmucosal adminstration forms of s-ketamine |
| US9468611B2 (en) | 2012-09-27 | 2016-10-18 | Relmada Therapeutics, Inc. | d-Methadone for the treatment of psychiatric symptoms |
| US10555916B2 (en) | 2013-01-25 | 2020-02-11 | Case Western Reserve University | NMDAR antagonist for the treatment of pervasive development disorders |
| DK2983787T3 (da) | 2013-04-12 | 2020-01-06 | Icahn School Med Mount Sinai | Fremgangsmåde til behandling af posttraumatisk stresssygdom |
| CA2922507C (en) | 2013-08-26 | 2022-07-05 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
| WO2015051259A1 (en) | 2013-10-04 | 2015-04-09 | Impax Laboratories, Inc. | Pharmaceutical compositions and methods of use |
| EA032013B1 (ru) | 2013-10-31 | 2019-03-29 | Сайма Лэбс Инк. | Препятствующие злоупотреблению гранулированные лекарственные формы с немедленным высвобождением |
| PL3287124T3 (pl) | 2014-04-17 | 2023-02-20 | Ketabon Gmbh | Doustna postać dawkowania ketaminy |
| AU2015318123A1 (en) * | 2014-09-15 | 2017-03-30 | Janssen Pharmaceutica Nv | Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression |
| DK3215147T3 (da) | 2014-11-04 | 2024-04-02 | Acadia Pharm Inc | Neurodæmpende norketamin-forbindelser og fremgangsmåder |
| WO2016094358A1 (en) | 2014-12-08 | 2016-06-16 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US20160338977A1 (en) | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
| WO2017041112A1 (en) | 2015-09-04 | 2017-03-09 | Cyprus Therapeutics, Inc. | Ketamine and cytochrome p 450 inhibitor combinations |
| US11110070B2 (en) | 2015-11-17 | 2021-09-07 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms |
| AU2017351437B2 (en) | 2016-10-27 | 2022-01-27 | National University Corporation Chiba University | Application of (S)-norketamine and salt thereof as pharmaceutical |
| ES2991544T3 (es) | 2016-11-30 | 2024-12-04 | Wolfson Philip E | Ketamina para el tratamiento de síntomas relacionados con la menstruación |
| WO2018234568A2 (en) | 2017-06-23 | 2018-12-27 | Develco Pharma Schweiz Ag | HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION |
| CN111630026A (zh) | 2017-10-10 | 2020-09-04 | 道格拉斯制药有限公司 | 缓释药物制剂和治疗方法 |
| KR20240011237A (ko) | 2017-12-22 | 2024-01-25 | 얀센 파마슈티카 엔브이 | 우울증 치료를 위한 에스케타민 |
| CN112702995A (zh) | 2018-10-05 | 2021-04-23 | 克雷西奥生物科技有限公司 | 治疗重度抑郁症的艾氯胺酮的治疗方案 |
| CA3133012A1 (en) | 2019-08-05 | 2021-02-11 | The Ketamine Research Foundation | Ketamine for the treatment of postpartum symptoms and disorders |
| TW202135787A (zh) | 2019-12-12 | 2021-10-01 | 比利時商健生藥品公司 | 艾氯胺酮調配物及製備與儲存的方法 |
| EP4084786A1 (en) | 2019-12-30 | 2022-11-09 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
-
2019
- 2019-06-27 BR BR112020023882-1A patent/BR112020023882A2/pt unknown
- 2019-06-27 IL IL278759A patent/IL278759B2/en unknown
- 2019-06-27 AU AU2019293515A patent/AU2019293515B2/en active Active
- 2019-06-27 US US16/454,399 patent/US12036189B2/en active Active
- 2019-06-27 KR KR1020207036721A patent/KR102793535B1/ko active Active
- 2019-06-27 EP EP19766075.6A patent/EP3813807A1/en active Pending
- 2019-06-27 JP JP2020569956A patent/JP2021529732A/ja active Pending
- 2019-06-27 CA CA3103440A patent/CA3103440A1/en active Pending
- 2019-06-27 MX MX2020012475A patent/MX2020012475A/es unknown
- 2019-06-27 WO PCT/IB2019/055453 patent/WO2020003195A1/en not_active Ceased
- 2019-06-27 CN CN201980034997.3A patent/CN112188889A/zh active Pending
-
2024
- 2024-01-09 JP JP2024000939A patent/JP2024041855A/ja active Pending
- 2024-07-15 US US18/772,474 patent/US20240366530A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021529732A5 (https=) | ||
| WO2021207409A3 (en) | Small molecule inhibitors of sars-cov-2 viral replication and uses thereof | |
| Montgomery et al. | Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability | |
| Cutler et al. | Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial | |
| BG108379A (bg) | Използване на енантиомерно чист есциталопрам | |
| JP2020504129A (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| Silva Filho et al. | Comment on “The importance of physical exercise during the coronavirus (COVID-19) pandemic” | |
| Kelmendi et al. | Clinical evidence for the use of methylone in the treatment of PTSD: A case series with long-term follow-up | |
| Lu et al. | Rapid and sustained improvement in treatment-refractory depression through use of acute intravenous ketamine and concurrent transdermal selegiline: A case series | |
| EP3393517B1 (en) | Acetylsalicylic acid for use in the treatment of moderate to severe influenza | |
| JP7312286B2 (ja) | うつ病を予防または治療するための安息香酸またはその塩および誘導体 | |
| Nikitina et al. | OPTIMIZATION OF PHARMACOTHERAPY STRATEGY FOR TREATMENT-RESISTANT DEPRESSION | |
| Alavi et al. | Tranquilizer/Anxiolytics: Pregabalin | |
| UA112652C2 (uk) | Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції | |
| Bedard et al. | P0174-Mindfulness-based cognitive therapy reduces depression symptoms in people with a traumatic brain injury: Results from a pilot study | |
| Sharma et al. | POS-416 TREATING HCV INFECTION IN CHRONIC KIDNEY DISEASE IN DEVELOPING COUNTRY: OUR EXPERIENCE WITH LIMITED RESOURCES | |
| RU2000129499A (ru) | Лечение депрессии и фармацевтические препараты для этой цели | |
| Cooper et al. | Improved health-related quality of life (HRQoL) and bleeding scores with oral bruton tyrosine kinase (BTK) inhibitor rilzabrutinib in the open-label (OL) period of the multicenter Phase 3 LUNA3 study in adults with immune thrombocytopenia (ITP) | |
| Zhang et al. | A Phase 2 Dose-Finding Trial of MY008211A in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria and Signs of Active Hemolysis | |
| Downey | A New Way To Manage Depression Without Drugs | |
| Vieta | Why do we consider major depressive disorder to be a chronic illness? | |
| Al-Noaemi Mohammed et al. | Drug Repositioning For The Prophylaxis And Treatment of COVID-19 | |
| TW202539680A (zh) | 組合物在製備用於治療至少一種癌症的用途 | |
| Bauer et al. | P0173-Effect of once-daily extended release Quetiapine Fumarate (Quetiapine XR) as add-on to antidepressants in major depressive disorder (MDD) | |
| Bauer et al. | P. 2. g. 003 Efficacy of adjunct quetiapine extendedrelease in major depressive disorder: a pooled analysis of SSRI and SNRI patient subgroups |